Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

MAIA details exceptional survival in third-line NSCLC at ESMO

MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3...

October 23, 2025

Developments

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve...

October 21, 2025

Developments

Tenon receives FDA 510(k) clearance for joint fusion system

Tenon Medical (NASDAQ:TNON) has announced that the FDA has granted 510(k) clearance for its SImmetry+ SI Joint Fusion System indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint...

October 21, 2025

Developments

USPTO publishes patent application for Clearmind’s MEAI for binge behavior disorders

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as...

October 20, 2025

Developments

Profound congratulates Busch Center for 500th TULSA procedure achieved

Profound Medical (NASDAQ: PROF; TSX: PRN) has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and...

October 16, 2025

Developments

Sunshine launches generic statin

Sunshine Biopharma (NASDAQ: SBFM) has announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Pravastatin—a generic prescription version of the drug Pravachol. Pravastatin is a statin medication...

October 16, 2025

Developments

Theravance launches education campaign for nOH associated with MSA

Theravance Biopharma (NASDAQ: TBPH) has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic...

October 16, 2025

Developments

First patient dosed in Adicet’s trial of ADI-001 in RA

Adicet Bio (NASDAQ: ACET) has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory rheumatoid arthritis (RA). The company’s Phase 1 study is designed...

October 16, 2025

Developments

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...

October 8, 2025

Developments

USPTO grants Aquestive two patents for Anaphylm

Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...

October 8, 2025

Developments

Profound sees record revenues in Q3-2025; up 84-87% YoY with higher gross margin

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of...

October 7, 2025

Developments

PharmaJet initiates development of needle-free injection pens for home use

Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...

October 7, 2025

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Developments

Aspire files omnibus patent application with USPTO for drug delivery platform

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology. According to Aspire, the technology is designed to enhance...

October 6, 2025

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Developments

Profusa adds leading CLTI surgeon to customer base

Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen...

October 1, 2025

Developments

Larimar reports positive data from study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered...

September 30, 2025

Developments

Anebulo announces first dose in SAD study of IV selonabant for ACI

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy...

September 26, 2025

Developments

ME secures U.S. patent for lead G-CSF antibody candidate

Me Therapeutics Holdings (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate. According to ME, the...

September 26, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Developments

CIPO grants NOA to Moleculin for patent covering Annamycin

Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with...

September 25, 2025

Developments

TGA approves MediWound’s NexoBrid for burn management in Australia

MediWound (NASDAQ: MDWD) has announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid—an enzymatic therapy for the removal of eschar in both adult and pediatric...

September 25, 2025

Subscribe